Xin Liu

PPM1L-dependent PD-L1 dephosphorylation orchestrates tumor-type-specific ubiquitin ligase recognition to govern its degradation.

As a powerful clinical strategy for cancer treatment, immune checkpoint blockage targeting the PD-1/PD-L1 axis is frequently hampered by diverse resistance mechanisms. An in-depth elucidation of the molecular mechanisms governing PD-L1 homeostasis is crucial for improving the immunotherapy response rate. Here, we demon...